KERENDIA Drug Patent Profile

Which patents cover Kerendia, and when can generic versions of Kerendia launch?

Kerendia is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has ninety-eight patent family members in fifty countries.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this compound. Additional details are available on the finerenone profile page.

DrugPatentWatch^® Generic Entry Outlook for Kerendia

Kerendia was eligible for patent challenges on July 9, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 29, 2035. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (finerenone), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for KERENDIA

International Patents:	98
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	6
Patent Applications:	296
Drug Prices:	Drug price information for KERENDIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KERENDIA
What excipients (inactive ingredients) are in KERENDIA?	KERENDIA excipients list
DailyMed Link:	KERENDIA at DailyMed

See drug prices for KERENDIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KERENDIA

NDA:

215341

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for KERENDIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Center Groningen	Phase 4
Boehringer Ingelheim	Phase 4
University of North Carolina, Chapel Hill	Phase 2

See all KERENDIA clinical trials

Pharmacology for KERENDIA

Drug Class	Nonsteroidal Mineralocorticoid-Receptor Antagonist
Mechanism of Action	Mineralocorticoid Receptor Antagonists

Paragraph IV (Patent) Challenges for KERENDIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KERENDIA	Tablets	finerenone	40 mg	215341	1	2026-02-02
KERENDIA	Tablets	finerenone	10 mg and 20 mg	215341	9	2025-07-09

US Patents and Regulatory Information for KERENDIA

KERENDIA is protected by two US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-001	Jul 9, 2021		RX	Yes	No			Y	Y
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-002	Jul 9, 2021		RX	Yes	Yes
Bayer Hlthcare	KERENDIA	finerenone	TABLET;ORAL	215341-001	Jul 9, 2021		RX	Yes	No

EU/EMA Drug Approvals for KERENDIA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Kerendia	finerenone	EMEA/H/C/005200Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	Authorised	no	no	no	2022-02-16

International Patents for KERENDIA

When does loss-of-exclusivity occur for KERENDIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

Chile

China

Colombia

Croatia

Denmark

European Patent Office

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KERENDIA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	065463
Australia	2008221071
Brazil	122020008544

Supplementary Protection Certificates for KERENDIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2132206	C02132206/01	Switzerland		PRODUCT NAME: FINERENON; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68130 26.11.2021
2132206	LUC00260	Luxembourg		PRODUCT NAME: FINERENONE, SES SELS ET SOLVATES AINSI QUE LES SOLVATES DES SELS DE FINERENONE; AUTHORISATION NUMBER AND DATE: EU/1/21/1616 20220217
2132206	PA2022512	Lithuania		PRODUCT NAME: FINERENONAS; REGISTRATION NO/DATE: EU/1/21/1616 20220216

Last updated: May 30, 2026

KERENDIA (finerenone) market dynamics and financial trajectory: sales drivers, growth path, payer pressure, and exclusivity risk

KERENDIA (finerenone) has transitioned from launch-market uptake to a segment where growth is increasingly tied to conversion of eligible CKD with T2D patients, formulary access for finerenone, persistence of background ACE inhibitor/ARB use, and incremental adoption of higher-acuity endpoints in clinical practice. Competitive dynamics are centered on steroidal MRA rivals (limited), newer SGLT2 inhibitors and GLP-1 RA cardiometabolic agents affecting kidney and cardiovascular management pathways, and payer scrutiny of high-cost add-ons in CKD. Financial trajectory is influenced by (1) continued performance against KDIGO-aligned treatment patterns, (2) expansion from cardiovascular nephrology to broader primary care and endocrinology ordering, and (3) patent and exclusivity timing that shapes generic and biosimilar or “authorized generic” risk.

Primary commercial takeaways:

• Growth is path-dependent on achieving broad formulary placement and maintaining net price amid Medicare Part D and commercial rebate structures.
• Market expansion is tied to identifying “eligible” CKD with T2D and sustaining adherence/persistence, because finerenone’s incremental benefit is realized on top of ACEi/ARB.
• Near-term competitive pressure is more payer- and pathway-driven than molecule-driven; finerenone competes for budget within CKD with T2D and cardiorenal risk management rather than as a direct drug-class substitute with the same label scope.
• Exclusivity and IP determine the magnitude of long-tail revenue risk rather than immediate competitive loss.

No complete market/financial dataset was provided for KERENDIA in the prompt (for example: company revenue disclosures, quarterly sales figures, segment guidance, payer contracting outcomes, OR FDA/Orange Book exclusivity milestones linked to a defined geography and label). Under the operating constraints, this prevents a complete, accurate financial trajectory and market-dynamics model from being produced here.

---

What are the key market dynamics driving KERENDIA (finerenone) adoption in CKD with type 2 diabetes?

How does clinician decision-making shape KERENDIA uptake?

Finerenone adoption is driven by three practical factors that determine real-world prescribing velocity:

1. Diagnostic capture and staging: identifying CKD with T2D patients meeting guideline thresholds for albuminuria and eGFR ranges where MRAs are used.
2. Background therapy enforcement: finerenone is typically used with maximally tolerated ACE inhibitors or ARBs; patients not on appropriate background therapy can slow conversion.
3. Safety workflow: hyperkalemia risk management affects uptake, especially early in therapy and in patients with lower baseline eGFR.

What payer levers affect KERENDIA net sales?

Payer influence shows up through:

• Formulary placement tiers and step edits for MRAs in CKD with T2D.
• Prior authorization requiring documentation of CKD staging and current ACEi/ARB use.
• Rebate intensity tied to outcomes or utilization controls, common for expensive cardiometabolic add-ons.

Where is utilization most likely to expand?

Market expansion typically follows ordering patterns:

• Nephrology and cardiology drive initiation in higher-acuity CKD and albuminuria.
• Endocrinology and primary care drive the broader “eligible pool” if formularies simplify access and if risk monitoring infrastructure is available.

---

How strong is KERENDIA’s competitive position versus SGLT2 inhibitors and GLP-1 receptor agonists in cardiorenal care?

Does finerenone compete directly with SGLT2 inhibitors?

Finerenone competes for budget and guideline adherence within the CKD with T2D population, but it is usually positioned as complementary to SGLT2 inhibitors. In practice, many payers and clinicians treat these as stackable risk reducers rather than mutually exclusive therapies, which can support total therapy intensity while increasing payer scrutiny.

How does KERENDIA compare with other MRAs?

Finerenone’s market power is influenced by:

• Steroidal, non-steroidal selectivity profile versus legacy MRAs (spiro/ eplerenone), which can affect tolerability and clinician preference.
• Label alignment around CKD with T2D and cardiovascular outcomes, which governs payer comfort and guideline adherence.

---

What patents protect KERENDIA (finerenone) and how do they affect market exclusivity timelines?

What exclusivity timing matters for generic entry risk?

The market-financial impact of exclusivity is governed by:

• Composition-of-matter coverage breadth.
• Formulation and dosing patents, which can delay “non-infringing” reformulations.
• Method-of-use and treatment regimen patents tied to CKD/albuminuria endpoints.

How does Orange Book status translate into revenue risk?

Orange Book-listed patents shape:

• Paragraph IV challenge probability and challenge strategy.
• Settlement leverage in Hatch-Waxman litigation.
• Authorized generic incentives post-launch.

A complete, accurate patent/Orange Book table and expiration timeline cannot be produced without the specific KERENDIA patent list and jurisdictional filings. The prompt provides no patent numbers, expiry dates, or Orange Book entries.

---

What is the financial trajectory for KERENDIA sales and profitability drivers (price, volume, mix)?

What determines KERENDIA revenue growth?

Finerenone revenue trajectories in CKD drugs typically depend on:

• Volume growth: expanding eligible patients, increasing initiation rates.
• Persistence: continued dosing after safe titration and monitoring.
• Net price: list price minus rebates and wholesaler/chargeback mechanics.
• Mix: higher share of patient segments with stronger adherence to risk monitoring.

What costs pressure margins?

• Commercial overhead and contracting costs tied to formulary access.
• Manufacturing scale and supply chain costs if volume grows faster than fixed cost absorption.
• Medical affairs spend for reimbursement support and outcomes evidence.

No KERENDIA sales history or financial statement extracts were included, so a quantified trajectory (annual revenue, YoY growth, operating margin, or guidance changes) cannot be built while maintaining accuracy.

---

What generic entry risks exist for KERENDIA, and when could they materialize?

Paragraph IV and settlement scenarios

For CKD add-on cardiovascular-nephrology drugs, entry risk depends on:

• Whether Orange Book patents include drug substance, formulation, or method-of-use.
• How many patents are simultaneously asserted in litigation.
• Likelihood of non-infringing design-arounds (new salts, polymorphs, or formulation pathways).

Biosimilar risk

Finerenone is a small molecule; biosimilar risk is not applicable.

Without the KERENDIA patent estate and Orange Book expiration set, any launch timing would be speculative and fails accuracy constraints.

---

How does KERENDIA’s prescribing economics compare across U.S. commercial, Medicare Part D, and Medicaid?

Commercial

• Rebates and formulary exclusions drive adoption.
• Step edits and prior auth can slow initiation but may increase persistence in approved networks.

Medicare Part D

• Formularies and Part D negotiations can materially change net utilization.
• Patient monitoring requirements can increase office workflow costs, influencing prescriber behavior.

Medicaid

• State formulary structures can accelerate or impede access depending on preferred drug lists and PDL compliance.

No payer coverage matrix, net-to-gross, or utilization share was supplied.

---

What patent litigation affects KERENDIA (finerenone) and how does it shape competitive timing?

Hatch-Waxman litigation is the gating factor for generic entry

The practical effect of litigation on market dynamics is usually:

• Temporary protection via injunctions or stay periods after litigation.
• Settlement terms can include delayed entry, license payments, and negotiated carve-outs.

No litigation docket, asserted patent numbers, or settlement dates were provided.

---

What formulations, strengths, and dosing regimens are protected for KERENDIA and how does that influence “design-around” risk?

Why formulation and dosing patents matter

Even with composition-of-matter protection, generics may seek:

• alternate polymorphs,
• modified-release formulations,
• different dosing titration regimens to seek non-infringing status.

How design-arounds affect market timing

If multiple formulation and method-of-use patents exist:

• generics need coordinated challenges or licensing,
• launch can be staged after resolution of different patent clusters.

Patent claim coverage for KERENDIA formulations and dosing is not present in the prompt.

---

Key Takeaways

• KERENDIA’s growth is primarily driven by CKD with T2D identification, formulary conversion, and safe titration workflows that sustain persistence.
• Competitive pressure is mostly pathway and payer-driven rather than a rapid direct substitution with another MRA or a molecule with overlapping label scope.
• The timing and breadth of the KERENDIA patent estate determines long-term revenue risk, including likelihood and timing of Paragraph IV challenges.
• A quantified financial trajectory and exclusivity timeline cannot be constructed accurately from the provided input.

---

FAQs

1. How does KERENDIA perform versus ACEi/ARB alone in real-world CKD with T2D populations?
2. What are the main reimbursement hurdles for finerenone in prior authorization and step-therapy policies?
3. How does hyperkalemia monitoring influence time-to-therapy and adherence for KERENDIA?
4. What is the likely impact of formulary exclusions on KERENDIA net price and volume?
5. What patent claim categories most commonly block generic entry for small-molecule CKD drugs like finerenone?

---

References

1. (No sources were provided in the prompt, and no cited KERENDIA-specific documents or datasets are available in the conversation to support a reference list.)

DrugChatter Q&A for KERENDIA

Is a generic version of kerendia planned?
Patent expiry datefor kerendia?
Patent expiration date kerendia?
Kerendia drug price in euro?
How much does kerendia cost?